UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 698

Sortiert nach

Individual magnitudes of neural variability quenching are associated with motion perception abilities

Journal of neurophysiology, 2021-04, Vol.125 (4), p.1111-1120

2021

Link zum Volltext

Verfügbarkeit prüfen

Treating Vasospasm with IV Milrinone: Relax (The Vessel) or Don’t Do It

Neurocritical care, 2023-10, Vol.39 (2), p.547-548

2023

Link zum Volltext

Verfügbarkeit prüfen

Where there is inflammation, treatment may reduce disability progression – No

Multiple sclerosis, 2018-12, Vol.24 (14), p.1810-1812

2018

Link zum Volltext

Verfügbarkeit prüfen

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Multiple sclerosis, 2022-07, Vol.28 (8), p.1277-1285

2022

Link zum Volltext

Verfügbarkeit prüfen

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Multiple sclerosis, 2021-10, Vol.27 (11), p.1760-1770

2021

Link zum Volltext

Verfügbarkeit prüfen

Oral rather than intravenous corticosteroids should be used to treat MS relapses – Yes

Multiple sclerosis, 2017-07, Vol.23 (8), p.1056-1058

2017

Link zum Volltext

Verfügbarkeit prüfen

Richard E Gonsette (1929–2014)

Multiple sclerosis, 2015-04, Vol.21 (5), p.540-540

2015

Link zum Volltext

Verfügbarkeit prüfen

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

Multiple sclerosis, 2020-07, Vol.26 (8), p.924-935

2020

Link zum Volltext

Verfügbarkeit prüfen

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Multiple sclerosis, 2021-03, Vol.27 (3), p.479-482

2021

Link zum Volltext

Verfügbarkeit prüfen

Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35)

Multiple sclerosis and related disorders, 2023-05, Vol.73, p.104657-104657, Article 104657

2023

Link zum Volltext

Verfügbarkeit prüfen

The Dot Counting Test adds up: Validation and response pattern analysis in a mixed clinical veteran sample

Journal of clinical and experimental neuropsychology, 2018-05, Vol.40 (4), p.317-325

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study

Journal of neurology, 2018-04, Vol.265 (4), p.917-925

2018

Link zum Volltext

Verfügbarkeit prüfen

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Multiple sclerosis, 2021-01, Vol.27 (1), p.90-96

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial

Journal of neurology, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Neurology : neuroimmunology & neuroinflammation, 2022-11, Vol.9 (6)

2022

Link zum Volltext

Verfügbarkeit prüfen

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up

Multiple sclerosis, 2018-12, Vol.24 (14), p.1852-1861

2018

Link zum Volltext

Verfügbarkeit prüfen

Toward Socially Aware Person-Following Robots

IEEE transactions on cognitive and developmental systems, 2018-12, Vol.10 (4), p.936-954

2018

Link zum Volltext
IEEE_Xplore

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients

Journal of neurology, 2022-10, Vol.269 (10), p.5571-5581

2022

Link zum Volltext

Verfügbarkeit prüfen

Cell-type-specific modulation of neocortical activity by basal forebrain input

Frontiers in systems neuroscience, 2013-01, Vol.6, p.79-79

2013

Link zum Volltext

Verfügbarkeit prüfen

Aggressive multiple sclerosis (1): Towards a definition of the phenotype

Multiple Sclerosis Journal, 2020-08, Vol.26 (9), p.1031-1044

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessing the experience of the quality of care of patients living with multiple sclerosis and their caregivers: The MusiCare questionnaire

European journal of neurology, 2021-03, Vol.28 (3), p.910-920

2021

Link zum Volltext

Verfügbarkeit prüfen

A 10-year follow-up of the European multicenter trial of interferon beta -1b in secondary-progressive multiple sclerosis

Multiple sclerosis, 2016-04, Vol.22 (4), p.533-543

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament-light chain in multiple sclerosis

Annals of clinical and translational neurology, 2021-05, Vol.8 (5), p.1141-1150

2021

Link zum Volltext

Verfügbarkeit prüfen

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Multiple sclerosis and related disorders, 2022-10, Vol.66, p.104072-104072, Article 104072

2022

Link zum Volltext

Verfügbarkeit prüfen

Aggressive multiple sclerosis (2): Treatment

Multiple Sclerosis Journal, 2020-08, Vol.26 (9), p.1045-1063

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 698

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

SpracheCroatian

ThemaHumans

ThemaNeurosciences & Neurology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(543)
Mit Volltextzugriff
(692)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Individual magnitudes of neural variability quenching are associated with motion perception abilities

Treating Vasospasm with IV Milrinone: Relax (The Vessel) or Don’t Do It

Where there is inflammation, treatment may reduce disability progression – No

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Oral rather than intravenous corticosteroids should be used to treat MS relapses – Yes

Richard E Gonsette (1929–2014)

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35)

The Dot Counting Test adds up: Validation and response pattern analysis in a mixed clinical veteran sample

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial

Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up

Toward Socially Aware Person-Following Robots

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients

Cell-type-specific modulation of neocortical activity by basal forebrain input

Aggressive multiple sclerosis (1): Towards a definition of the phenotype

Assessing the experience of the quality of care of patients living with multiple sclerosis and their caregivers: The MusiCare questionnaire

A 10-year follow-up of the European multicenter trial of interferon beta -1b in secondary-progressive multiple sclerosis

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament-light chain in multiple sclerosis

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Aggressive multiple sclerosis (2): Treatment

Aktive Filter

Suchergebnisse filtern